Skip to content
Search

Latest Stories

NHS virtual wards set to slash waiting times, prevent 178k admissions in next 2 years

NHS virtual wards set to slash waiting times, prevent 178k admissions in next 2 years
Under the new NHS virtual wards scheme, hospitals to be incentivised for prompt care, with 12-hour A&E target

In a strategic move to enhance healthcare delivery, the NHS has announced plans to intensify the utilisation of virtual wards under the the Urgent and Emergency Care Recovery Plan.

The NHS virtual wards are aimed to reduce avoidable hospital admissions across England.


This follows a comprehensive analysis revealing significant benefits from virtual wards over the past year.

"Virtual wards offer a transformative approach to healthcare delivery, allowing patients to receive medical care from the comfort of their own homes," remarked NHS national director for urgent and emergency care, Sarah-Jane Marsh.

"This initiative not only reduces the burden on hospital resources but also ensures that patients receive timely and personalised care."

Virtual wards aim to cater to individuals with respiratory conditions, heart failure, and frailty.

Thereby, providing access to treatment such as intravenous therapy or nebuliser treatment remotely, thus contributing to a reduction in hospital bed occupancy.

"The success of virtual wards in preventing hospital admissions has been remarkable," stated Marsh.

"In the South East region alone, over 9,000 admissions were prevented in the past year, highlighting the significant impact of this innovative approach."

Extrapolating from this success, NHS analysis suggests that nationwide implementation of virtual wards could potentially prevent 178,000 admissions over the next two years.

This strategic shift is supported by a directive from NHS England, outlining evidence-based measures to bolster urgent and emergency care performance.

Notably, hospitals are encouraged to prioritise prompt patient management, with financial incentives tied to achieving a maximum 12-hour wait time in A&E.

"Our aim is to ensure that patients receive the care they need in a timely and efficient manner," remarked Minister for Urgent and Emergency Care, Helen Whately.

"By expanding virtual ward provisions and implementing targeted interventions, we can alleviate pressure on hospital services and improve patient outcomes," she further added.

The multifaceted approach outlined in the NHS directive includes streamlined clinical assessment processes and enhanced frailty evaluations.

It also includes measures to enhance workforce flexibility and retention.

With stringent targets in place, the NHS aims to usher in a new era of healthcare delivery characterised by enhanced efficiency and patient-centered care.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less